The other PI3Kα inhibitor Alpelisib is approved by FDA for use with fulvestrant to treat male and postmenopausal female patients with PIK3CA‐mutated, HR‐positive/HER2‐negative advanced breast cancer that has progressed during or after endocrine therapy [17]. Here, ERBB2 is linked to breast carcinoma.